Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for prevention of camrelizumab-induced RCCEP in advanced NSCLC
ChiCTR2400083162Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of thalidomide and camrelizumab in non-small cell lung cancer (NSCLC), sponsored by The Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Incidence of reactive cutaneous capillary endothelial proliferation. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
thalidomidecamrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400083162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083162.